46.61 USD
+0.42 (+0.91%)
46.61 USD
0 (0%)
Overall EXEL gets a fundamental rating of 8 out of 10. We evaluated EXEL against 530 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. This makes EXEL very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
EXEL had positive earnings in the past year.
EXEL had a positive operating cash flow in the past year.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 24.01%, EXEL belongs to the top of the industry, outperforming 97.36% of the companies in the same industry.
EXEL has a Return On Equity of 31.37%. This is amongst the best in the industry. EXEL outperforms 97.74% of its industry peers.
EXEL's Return On Invested Capital of 26.31% is amongst the best of the industry. EXEL outperforms 98.87% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 18.22%.
The last Return On Invested Capital (26.31%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
The Profit Margin of EXEL (29.63%) is better than 95.66% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
The Operating Margin of EXEL (35.85%) is better than 97.55% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 96.63%, EXEL belongs to the top of the industry, outperforming 96.60% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has less shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EXEL has an Altman-Z score of 13.36. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL's Altman-Z score of 13.36 is amongst the best of the industry. EXEL outperforms 84.72% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 13.36 |
ROIC/WACC2.99
WACC8.81%
2.3 Liquidity
EXEL has a Current Ratio of 3.75. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Current ratio (3.75) which is in line with its industry peers.
EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Quick ratio (3.68) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.51% over the past year.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 9.93% in the last year.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
The Earnings Per Share is expected to grow by 25.76% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.99% on average over the next years. This is quite good.
EPS Next Y39.79%
EPS Next 2Y29.02%
EPS Next 3Y29.08%
EPS Next 5Y25.76%
Revenue Next Year7.88%
Revenue Next 2Y9.88%
Revenue Next 3Y11.62%
Revenue Next 5Y9.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EXEL is valuated rather expensively with a Price/Earnings ratio of 19.67.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 94.72% of the companies are valued more expensively.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.61.
The Price/Forward Earnings ratio is 15.14, which indicates a correct valuation of EXEL.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.23% of the companies in the same industry.
EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.01, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.67 | ||
| Fwd PE | 15.14 |
4.2 Price Multiples
95.66% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.03 | ||
| EV/EBITDA | 12.69 |
4.3 Compensation for Growth
EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 29.08% in the coming years.
PEG (NY)0.49
PEG (5Y)1.56
EPS Next 2Y29.02%
EPS Next 3Y29.08%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
46.61
+0.42 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.38%
Inst Owner Change-0.35%
Ins Owners2.17%
Ins Owner Change-2.56%
Market Cap12.50B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target45.9 (-1.52%)
Short Float %8.14%
Short Ratio7.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)2.52%
PT rev (3m)1.38%
EPS NQ rev (1m)7.84%
EPS NQ rev (3m)22.93%
EPS NY rev (1m)7.89%
EPS NY rev (3m)9.42%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.67 | ||
| Fwd PE | 15.14 | ||
| P/S | 5.46 | ||
| P/FCF | 16.03 | ||
| P/OCF | 15.8 | ||
| P/B | 5.78 | ||
| P/tB | 5.96 | ||
| EV/EBITDA | 12.69 |
EPS(TTM)2.37
EY5.08%
EPS(NY)3.08
Fwd EY6.61%
FCF(TTM)2.91
FCFY6.24%
OCF(TTM)2.95
OCFY6.33%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.49
PEG (5Y)1.56
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 13.36 |
F-Score8
WACC8.81%
ROIC/WACC2.99
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y39.79%
EPS Next 2Y29.02%
EPS Next 3Y29.08%
EPS Next 5Y25.76%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.88%
Revenue Next 2Y9.88%
Revenue Next 3Y11.62%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.05%
EBIT Next 3Y25.06%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 19.67 and the Price/Book (PB) ratio is 5.78.